Literature DB >> 36004135

Reply: Can you really turn a vein into an artery?

Piotr Mazur1, Juan A Crestanello1.   

Abstract

Entities:  

Year:  2021        PMID: 36004135      PMCID: PMC9390563          DOI: 10.1016/j.xjon.2021.09.011

Source DB:  PubMed          Journal:  JTCVS Open        ISSN: 2666-2736


× No keyword cloud information.
Reply to the Editor: The authors reported no conflicts of interest. The Journal policy requires editors and reviewers to disclose conflicts of interest and to decline handling or reviewing manuscripts for which they may have a conflict of interest. The editors and reviewers of this article have no conflicts of interest. The choice of conduit to supplement the left internal thoracic artery (LITA) during coronary artery bypass grafting remains a subject of debate. Saphenous vein graft (SVG) is prone to failure, and its failure can occur in up to 12% of patients within the first 6 months postcoronary artery bypass grafting and in up to 46% within 1 year., In contrast, data supporting the use of additional arterial grafts are strong. Clinical outcomes are improved with addition of other arterial grafts to LITA–left anterior descending coronary artery, reducing the rates of early major adverse cardiac and cerebrovascular events and conferring a survival benefit after 15 years compared with SVG or percutaneous interventions. The choice of right internal mammary artery as the second arterial graft is often obvious for anatomical reasons and its excellent patency rates (96.9%), even if it is used as a free graft. In a recent study of 1325 patients who received in situ bilateral internal thoracic artery grafts to left coronary bed as a part of total arterial revascularization, the rate of graft failure after 18 years of follow-up was 1.6% for LITA, 2.9% for right internal mammary artery, and as high as 20.7% for the radial artery, which was used as a free graft to the right coronary bed. Hwang and colleagues reported that the use of SVG as a part of composite graft (SVG off the LITA) confers similar results as the use of multiple arterial grafts. The 10-year patency rates reported by Hwang and colleagues were excellent: 96.6% in the composite SVG group and 91.4% in the multiple arterial group. These findings are supported by the report of Lobo Filho and colleagues. They attribute these remarkable results to the use of valveless vein segments, to the avoidance of the proximal aortic anastomosis, and to the physiological effects of the proximal anastomosis to the LITA. While the “unique results in certain hands” are certainly commendable, it is hard to prove that “veins can be turned in to arteries” with similar outcomes and patency rates as multiarterial revascularization. Confirmation from additional studies and investigators will be needed before widespread use of this technique. In the meantime, while composite grafts using SVG off an arterial graft constitute an interesting alternative, most surgeons would probably prefer not to risk the compromise of the LITA–left anterior descending coronary artery graft. In the end, no matter how good the vein extension or Y-grafting technique is, one might argue nothing is better than an undisturbed arterial graft.
  10 in total

1.  Fate of venous grafts: the past, the present and the future.

Authors:  M G Bourassa
Journal:  J Am Coll Cardiol       Date:  1991-04       Impact factor: 24.094

2.  The growth potential and patency of free right internal thoracic arteries verified by CT angiography.

Authors:  Tadashi Isomura; Masanori Hirota; Minoru Yoshida; Shunsuke Yamagishi; Kohei Sumi; Shigehiko Yoshida
Journal:  Ann Thorac Surg       Date:  2021-01-20       Impact factor: 4.330

3.  Saphenous vein as secondary conduit in a Y-composite graft with the left internal thoracic artery.

Authors:  José Glauco Lobo Filho; Heraldo Guedis Lobo Filho; Matheus Duarte Pimentel
Journal:  J Thorac Cardiovasc Surg       Date:  2019-04       Impact factor: 5.209

Review 4.  Multiple arterial grafts improve late survival of patients undergoing coronary artery bypass graft surgery: analysis of 8622 patients with multivessel disease.

Authors:  Chaim Locker; Hartzell V Schaff; Joseph A Dearani; Lyle D Joyce; Soon J Park; Harold M Burkhart; Rakesh M Suri; Kevin L Greason; John M Stulak; Zhuo Li; Richard C Daly
Journal:  Circulation       Date:  2012-07-18       Impact factor: 29.690

5.  Efficacy and safety of edifoligide, an E2F transcription factor decoy, for prevention of vein graft failure following coronary artery bypass graft surgery: PREVENT IV: a randomized controlled trial.

Authors:  John H Alexander; Gail Hafley; Robert A Harrington; Eric D Peterson; T Bruce Ferguson; Todd J Lorenz; Abhinav Goyal; Michael Gibson; Michael J Mack; Daniel Gennevois; Robert M Califf; Nicholas T Kouchoukos
Journal:  JAMA       Date:  2005-11-16       Impact factor: 56.272

6.  Multiarterial grafts improve the rate of early major adverse cardiac and cerebrovascular events in patients undergoing coronary revascularization: analysis of 12 615 patients with multivessel disease.

Authors:  Chaim Locker; Hartzell V Schaff; Richard C Daly; Malcolm R Bell; Robert L Frye; John M Stulak; Sameh M Said; Joseph A Dearani; Lyle D Joyce; Kevin L Greason; Alberto Pochettino; Zhuo Li; Ryan J Lennon; Amir Lerman
Journal:  Eur J Cardiothorac Surg       Date:  2017-10-01       Impact factor: 4.191

7.  Multiple arterial grafts improve survival with coronary artery bypass graft surgery versus conventional coronary artery bypass grafting compared with percutaneous coronary interventions.

Authors:  Chaim Locker; Hartzell V Schaff; Richard C Daly; Joseph A Dearani; Malcolm R Bell; Robert L Frye; Kevin L Greason; John M Stulak; Lyle D Joyce; Alberto Pochettino; Zhuo Li; Ryan J Lennon; Amir Lerman
Journal:  J Thorac Cardiovasc Surg       Date:  2016-04-13       Impact factor: 5.209

8.  In situ skeletonized bilateral thoracic artery for left coronary circulation: a 20-year experience.

Authors:  Massimo Bonacchi; Edvin Prifti; Marco Bugetti; Francesco Cabrucci; Michael Cresci; Fabiana Lucá; Orlando Parise; Francesco Matteucci; Guido Sani; Daniel M Johnson; Sandro Gelsomino
Journal:  Eur J Cardiothorac Surg       Date:  2020-01-01       Impact factor: 4.191

9.  Apples remain apples NO matter what.

Authors:  Chaim Locker
Journal:  J Thorac Cardiovasc Surg       Date:  2019-01-23       Impact factor: 5.209

10.  Equivalent 10-year angiographic and long-term clinical outcomes with saphenous vein composite grafts and arterial composite grafts.

Authors:  Ho Young Hwang; Yeiwon Lee; Suk Ho Sohn; Jae Woong Choi; Ki-Bong Kim
Journal:  J Thorac Cardiovasc Surg       Date:  2020-04-08       Impact factor: 5.209

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.